Dana Mackie

Launched Otezla, a first in class oral PDE4 inhibitor for moderate to severe psoriasis and psoriatic arthritis, to Dallas area dermatologists. With a laser focus on top prescribing dermatology providers and developing strong relationships with KOL's, Otezla became the #1 prescribed systemic for Psoriasis patients starting systemic therapy.

• 2024 Dallas District MVP
• Team Excellence Award 2020 & 2022
• 2022 Chairman's Club Winner #5 of 126 reps
• 2020 Top 25%
• 2020 Promotion to Executive Sales Representative - Top 20% ranking for 3 out of 4 semester bonus periods and demonstrating Expert/Mentor level competencies
• 2019 Top 15% (missed President's Club by one spot)
• 2018 President's Club Winner #15 of 126 reps
• 2017 Top 20%
• 2016 Top 30%
• 2014 Top 25%

Promoted Cardene IV RTU premixed bags and Curosurf to hospital call points including ER, Surgery, ICU, NICU, and Pharmacy. Responsible for managed care pricing agreements and converting NICUs over to Curosurf. Worked with stroke coordinators to establish protocols for utilizing Cardene IV post stroke. Launched Bethkis and promoted Pertzye in Cystic Fibrosis Rare Disease market.

• 2013 #8 of 50 reps
• 100%+ Cardene IV Goal attainment Q1 2014, Q4 2013, Q3 2013, and Q2 2013
• 100%+ Curosurf Goal attainment for Q1 2014, Q4 2013, Q3 2013, and Q2 2013
• 133% Bethkis goal Attainment and 300% Pertzye goal attainment - Q1 2014
• Converted two NICUs to Curosurf

Launched and sold IV antibiotics and IV/oral PPI to hospitals and long term care facilities while providing clinical support to infectious disease, general surgeons, pulmonologists, ER, critical care, hospitalists, wound care, pharmacy, nursing staff, and microbiology labs.

• 2006 Presidential Achievement Award
• "Above & Beyond" District Recipient 2006
• Launched and gained formulary acceptance for Tygacil IV at all accounts with consistent pull through to meet and exceed sales goals
• Achieved Protonix preferred PPI status at all accounts and maintained preferred status despite allocation issues and high competitor activity
• Positioned Zosyn IV on two ER clinical pathways as the workhorse antibiotic at largest account and provided workable solutions to meet existing demand during supply issues

Launched and promoted Effexor XR and Sonata to psychiatrists in the DFW market. Cultivated key psychiatry advocates into local and national speakers. Recognized as a national role model in Wyeth sales developer publications & Working Mother magazine. Awarded first ever job share at Wyeth.

• 4X Presidential Gold Circle Award (top 2%) 2001, 1999, 1998, 1996
• Launched and maintained the #1 Effexor XR market share in the nation (out of 600 reps)- triple the national market share
• Ranked #1 Psych rep for eight consecutive years
• Grew Effexor XR sales to #1 antidepressant prescribed in territory - first rep in the nation to surpass Prozac and maintained the #1 position from 1998-2005
• Field Trainer Promotion 1997
• 2000 Sonata Dream Team Award - grew Sonata market share to twice the national average

Promoted Wyeth portfolio of products to cardiologists, orthopedic surgeons, rheumatologists, internal medicine, ER, and family practice. Ranked #1 in district and #2 in region on total bonus products in 1993.